Navigation Links
New diagnostic tool determines aggressiveness of prostate cancer

One in six men will be diagnosed with prostate cancer during his lifetime, the second leading cause of death among men in the United States.

It's a serious problem and current diagnostic tests aren't very specific. But a research team at the University of Central Florida NanoScience Technology Center has found a more accurate test that not only determines whether a patient has prostate cancer, but also how aggressive it is.

"That's really what is unique and exciting about our new discovery," said associate professor Qun "Treen" Huo, the lead investigator on the project. "Our nanoparticles not only seek out a chemical reaction that is specific to prostate cancer, they can also tell us how aggressive the cancerous cells are likely to be, which can give doctors better information to treat their patients."

Current tests can't tell how aggressive the cancer is, which often leads to the gland's removal when other options might be available. For example, a very aggressive type of cancer in a young man may require immediate removal of his prostate gland to save his life. A slow-acting cancer in a young patient may give him more options that are less radical.

And options are good because the prostate is a very important gland. It helps regulate urine flow and is involved in the production of semen in men. The effects of surgical removal of the prostate gland can range from mild loss of erection and pain on orgasm, to total loss of erection and incontinence.

Huo's work is published in the Journal of Translational Medicine at The technique is rather simple, Huo said.

She uses gold nanoparticles that detect a specific chemical reaction between a prostate tumor and the human immunoglobulin G (IgG). IgG is an abundant protein circulating in the blood. Research has shown that IgG likes to stick to the surface of the gold nanoparticles to form a protein corona. This corona can be detected by a technique called dynamic light scattering. Huo found that when cancer cells are present, they can "destroy" the IgG in the blood, and this specific interaction is picked up by the gold nanoparticles. Using this simple test, Huo can determine quantitatively how aggressive the prostate tumors are and the likelihood they will metastasize. The team tested out the technique on human tissue samples.

"We've had already done our study with animal and human blood samples," (J. Nanobiotechnology, ) Huo said. "Now we've confirmed our findings in both animal models and human tissue samples. I am in the process of conducting a validation study with the Florida Hospital Cancer Institute and I am very confidant the technology works."

If all goes well, clinical trials could begin in two to three years, and Huo hopes the diagnostic tool could be routinely used by physicians in as little as five years. The test most likely would be used to supplement those already used to provide doctors with more quantitative and accurate information, which could lead to more treatment options

The system that detects the reaction was discovered in Huo's lab four years ago. It's called "nanoparticle-enabled dynamic light scattering assay (NanoDLSay) and it is being used by many researchers around the world for everything from detecting cancer in blood to finding lead in water.

"We're looking for funding now to get to the next step," Huo said. The National Science Foundation and the Florida Department of Health Bankhead-Coley Foundation funded a lot of the basic research that went into creating the new technology.

"Ultimately it's about working together to help doctors help patients," Huo said. "That's why I research cancer. I want to help make that happen."

Contact: Zenaida Gonzalez Kotala
University of Central Florida

Related biology news :

1. Immunosignaturing: An accurate, affordable and stable diagnostic
2. 2012 Forecast for US Molecular Diagnostics Market Now Available From Global Information Inc.
3. Genetic abnormality offers diagnostic hope for childrens cancer
4. Ambry Genetics Reports Results from Clinical Diagnostic Exome™ Testing of Three Patients
5. Aria Diagnostics announces publication of first peer-reviewed data for new noninvasive prenatal test
6. Lung cancer conference to focus on new diagnostic techniques, potential treatments
7. Combination HPV diagnostic test for head and neck cancer outperformed other tests
8. First field-based molecular diagnostic test for African sleeping sickness in sight
9. ASU and Chinas Sun Yat-Sen University to develop early diagnostics against colorectal cancer
10. Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index™
11. Faster diagnostics through cheap, ultra-portable blood testing
Post Your Comments:
Related Image:
New diagnostic tool determines aggressiveness of prostate cancer
(Date:11/12/2015)...  Arxspan has entered into an agreement with ... use of its ArxLab cloud-based suite of biological ... will support the institute,s efforts to electronically manage ... internally and with external collaborators. The ArxLab suite ... Institute,s electronic laboratory notebook, compound and assay registration, ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/2/2015)... Nov. 2, 2015  SRI International has been awarded ... preclinical development services to the National Cancer Institute (NCI) ... provide scientific expertise, modern testing and support facilities, and ... pharmacology and toxicology studies to evaluate potential cancer prevention ... The PREVENT Cancer Drug Development Program is an NCI-supported ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... , November 27, 2015 ... Growing popularity of companion diagnostics is ... cancer biomarkers market with pharmaceutical companies and ... companion diagnostic tests. . ... Complete report on global cancer biomarkers ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... , November 25, 2015 Studies ... and human plaque and pave the way for more effective ... in cats     --> ... commonly diagnosed health problems in cats, yet relatively little was ... Two collaborative studies have been conducted by researchers from the ...
Breaking Biology Technology: